Safety and efficacy of Philips' Stellarex .035 low-dose drug-coated balloon demonstrated in clinical trials at three years - Associated Press

Safety and efficacy of Philips' Stellarex .035 low-dose drug-coated balloon demonstrated in clinical trials at three years  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more